A bayesian reanalysis of the phase III aducanumab (ADU) trial

TL;DR

This paper reanalyzes the phase III aducanumab trial data using Bayesian methods, revealing very low evidence of efficacy and providing clearer insights for future Alzheimer's research.

Contribution

It introduces a Bayesian reanalysis of clinical trial data, offering a new perspective on aducanumab's efficacy beyond traditional statistical approaches.

Findings

Evidence for drug efficacy is very low.

Bayesian analysis clarifies the trial results.

Provides a framework for future clinical trial assessments.

Abstract

In this article we have conducted a reanalysis of the phase III aducanumab (ADU) summary statistics announced by Biogen, in particular the result of the Clinical Dementia Rating-Sum of Boxes (CDR-SB). The results showed that the evidence on the efficacy of the drug is very low and a more clearer view of the results of clinical trials are presented in the Bayesian framework that can be useful for future development and research in the field.